These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 27486658)
1. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation. Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658 [TBL] [Abstract][Full Text] [Related]
2. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus. Zingaropoli MA; Iannetta M; Pontecorvo S; Anzivino E; Prezioso C; Rodio DM; Morreale M; D'Abramo A; Oliva A; Lichtner M; Cortese A; Frontoni M; Pietropaolo V; Francia A; Mastroianni CM; Vullo V; Ciardi MR Biomed Res Int; 2018; 2018():5297980. PubMed ID: 29682547 [TBL] [Abstract][Full Text] [Related]
3. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab. Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788 [TBL] [Abstract][Full Text] [Related]
4. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study. Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618 [TBL] [Abstract][Full Text] [Related]
5. Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients. Iannetta M; Zingaropoli MA; Latronico T; Pati I; Pontecorvo S; Prezioso C; Pietropaolo V; Cortese A; Frontoni M; D'Agostino C; Francia A; Vullo V; Mastroianni CM; Liuzzi GM; Ciardi MR Sci Rep; 2019 Jan; 9(1):311. PubMed ID: 30670793 [TBL] [Abstract][Full Text] [Related]
6. The effect of plasma exchange on serum anti-JC virus antibodies. Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602 [TBL] [Abstract][Full Text] [Related]
7. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis. Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785 [TBL] [Abstract][Full Text] [Related]
9. Asymptomatic reactivation of JC virus in patients treated with natalizumab. Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227 [TBL] [Abstract][Full Text] [Related]
10. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification. Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670 [TBL] [Abstract][Full Text] [Related]
11. High cumulative JC virus seroconversion rate during long-term use of natalizumab. Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481 [TBL] [Abstract][Full Text] [Related]
12. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy. Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472 [TBL] [Abstract][Full Text] [Related]
13. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients. Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052 [TBL] [Abstract][Full Text] [Related]
14. Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment. Pietropaolo V; Bellizzi A; Anzivino E; Iannetta M; Zingaropoli MA; Rodio DM; Morreale M; Pontecorvo S; Francia A; Vullo V; Palamara AT; Ciardi MR J Neurovirol; 2015 Dec; 21(6):653-65. PubMed ID: 25930159 [TBL] [Abstract][Full Text] [Related]
15. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients. Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276 [TBL] [Abstract][Full Text] [Related]